- Home
- AVAV vs SWTX Comparison
AVAV vs SWTX Comparison
Compare AVAV & SWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVAV
- SWTX
- Stock Information
- Founded
- AVAV 1971
- SWTX 2017
- Country
- AVAV United States
- SWTX United States
- Employees
- AVAV N/A
- SWTX N/A
- Industry
- AVAV Aerospace
- SWTX Biotechnology: Pharmaceutical Preparations
- Sector
- AVAV Industrials
- SWTX Health Care
- Exchange
- AVAV Nasdaq
- SWTX Nasdaq
- Market Cap
- AVAV 4.3B
- SWTX 3.5B
- IPO Year
- AVAV 2007
- SWTX 2019
- Fundamental
- Price
- AVAV $165.47
- SWTX $46.26
- Analyst Decision
- AVAV Buy
- SWTX Buy
- Analyst Count
- AVAV 6
- SWTX 7
- Target Price
- AVAV $202.40
- SWTX $56.86
- AVG Volume (30 Days)
- AVAV 363.4K
- SWTX 8.7M
- Earning Date
- AVAV 06-25-2025
- SWTX 05-20-2025
- Dividend Yield
- AVAV N/A
- SWTX N/A
- EPS Growth
- AVAV N/A
- SWTX N/A
- EPS
- AVAV 1.17
- SWTX N/A
- Revenue
- AVAV $742,556,000.00
- SWTX $191,589,000.00
- Revenue This Year
- AVAV $12.14
- SWTX $86.36
- Revenue Next Year
- AVAV $22.09
- SWTX $69.02
- P/E Ratio
- AVAV $140.85
- SWTX N/A
- Revenue Growth
- AVAV 5.21
- SWTX 3417.33
- 52 Week Low
- AVAV $102.25
- SWTX $28.21
- 52 Week High
- AVAV $236.60
- SWTX $62.00
- Technical
- Relative Strength Index (RSI)
- AVAV 66.67
- SWTX 58.93
- Support Level
- AVAV $154.39
- SWTX $46.10
- Resistance Level
- AVAV $169.00
- SWTX $46.27
- Average True Range (ATR)
- AVAV 6.26
- SWTX 0.90
- MACD
- AVAV 1.42
- SWTX 0.58
- Stochastic Oscillator
- AVAV 86.83
- SWTX 99.46
About AVAV AeroVironment Inc.
AeroVironment Inc operates under a single business segment in which it supplies unmanned aircraft systems, tactical missile systems, high-altitude pseudo-satellites, and other related services to government agencies within the United States Department of Defense as well as the United States allied international governments. The systems can help with security, surveillance, or sensing, and provide eyes in the sky without needing an actual person, or driver in the sky.
About SWTX SpringWorks Therapeutics Inc.
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.